• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Markets
    • Venture Capital
  • About
  • Contact

AbCellera Receives $175.6 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs

May 3, 2020 By admin Leave a Comment

AbCellera’s world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19

AbCellera announced today it has received a commitment of up to $175.6 million in support from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

AbCellera’s antibody discovery platform is being used to search blood samples of patients who have recovered from COVID-19 to aid in the discovery of antibodies that can be used to treat and prevent the disease. Since receiving one of the first North American samples from a recovered patient on February 25th, AbCellera has identified over 500 unique human anti-SARS-CoV-2 antibodies as part of a collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health. Antibodies discovered by AbCellera may also be used to create new diagnostic tests to support the medical community in monitoring the spread of COVID-19.

“Our government is mobilizing its resources to confront COVID-19, supporting the researchers and businesses that are working hard to develop medical countermeasures to beat this pandemic. Today’s contribution will support AbCellera Biologics as they use their world-leading technology to rapidly identify solutions for COVID-19 while ensuring Canada’s long-term preparedness for future health challenges,” stated the Honourable Navdeep Bains, Minister of Innovation, Science and Industry.

AbCellera previously announced a partnership with Eli Lilly and Company that seeks to develop a treatment for COVID-19 with the goal of beginning clinical trials in July 2020. As part of the collaboration, Lilly will independently fund and lead clinical development and testing of antibody therapeutics discovered through this partnership.

“Each and every one of us is affected, and our teams stand together, galvanized to fight this outbreak,” said Carl Hansen, Ph.D., CEO of AbCellera. “We are proud to have the support of the Government of Canada to quickly find solutions to the COVID-19 pandemic.”

The Strategic Innovation Fund is quickly deploying support to Canadian companies that are working on large-scale and later-stage promising research and development projects aimed at providing medical countermeasures to COVID-19, including vaccines and critical medical supplies.

In addition to the support from the Government of Canada, AbCellera is receiving support from the City of Vancouver. “The City of Vancouver is fully committed to ensuring AbCellera has the infrastructure needed as they accelerate finding a treatment for COVID-19,” said Mayor Kennedy Stewart, City of Vancouver. “We couldn’t be more proud to be on the front lines of this global effort thanks to the innovation and leadership of AbCellera.”

Phase 1 of the project will improve and apply AbCellera’s world-leading antibody discovery platform to identify fully human antibodies for the potential prevention and treatment of COVID-19 and future pandemics. Phase 2 will build a Good Manufacturing Practice (GMP) facility in Vancouver, BC. This facility will be the first in Canada capable of going from a patient sample to manufacturing antibodies for clinical testing, and will help Canada be prepared to respond to future pandemics.

About the P3 Program

AbCellera has spent the past two years adapting its technology to rapidly respond to pandemics through its participation in the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3). The goal of AbCellera’s four-year, USD $30M P3 project is to establish a robust pandemic response platform that can develop field-ready antibody drugs within 60 days of isolating an emerging viral pathogen.

About AbCellera Biologics Inc.

AbCellera is a privately held Canadian biotech with a drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, big data, machine learning, bioinformatics and genomics, identifies new first-in-class drugs and reduces the time it takes to bring treatments to clinic. AbCellera’s partners include leading biotechnology companies, global health organizations and six of the top 10 biopharmaceutical companies. AbCellera was founded in 2012, and completed a Series A financing round in 2018, which was led by DCVC Bio. For more information, visit www.abcellera.com.

Approved for Public Release. Distribution Unlimited.

Contacts

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Unfulfilled Dreams: The Aftermath of China’s Stalled Real Estate Developments
Huawei on the Brink: Biden Administration Considers Cutting Off the Tech Giant”
Key Fire Industry Trends for 2023
The Future of Food: Top Trends to Watch in 2023 and Beyond
How to discover the treasure trove of hidden marketing insights by watching customer behavior
Navigating Uncertainty: Prioritizing Hydrogen R&D Efforts for a Sustainable Future
Unleashing the Hidden Talent Pool: The Rise of STARs – Skilled Through Alternative Routes

Market Research Media

Turn Your Story into a Game: The Art of Gamifying Your Plot
The end of cheap money is redrawing the map of corporate earnings
The Future of Virtual Reality: How VR is Changing Industries
Market Research Media Survey: The State of Streaming Services
Media measurement services provide a holistic view of cross-media consumption
Gen Z ranks top in luxury sales
How to market recycled products

Secondary Sidebar

Tech Events

The crypto world is facing a crisis of confidence
ScyllaDB Summit 2023 taking place online on February 15-16, 2023
DLD 2023, an innovation festival, February 1-3, 2023, Tel Aviv, Israel
Cybersecurity Innovations Take Center Stage at Cybertech 2023 in Tel Aviv
Chiplet Summit, January 24-26 2023, the Doubletree by Hilton San Jose Hotel

Venture Capital

The Importance of Diversity and Inclusion in the Workplace
Sequoia Capital announces its $195 Mln dedicated seed fund
Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
actyv.ai Raises Pre-Series A Funding to Fuel Global Expansion, Product Enhancement
Ottopia announces $14.5M Series A Funding Round

Footer

Recent Posts

  • The Rise of Virtual Power Plants: Innovating Energy Management
  • DLD 2023 is coming
  • Barcelona Cybersecurity Congress Has Been a Success
  • The Unstoppable Rise of RISC V Architecture
  • Revolutionizing Education: The Power of Automated Tutoring Lessons
  • Revolutionizing the Fashion Industry: Algae-based Yarns and Dyes Take on Fast Fashion
  • Cybertech 2023 kicks off in Tel Aviv
  • Reducing Waste, Saving Energy: How Water Companies Can Recycle Residual Heat Energy
  • China’s Quest for Indigenized Semiconductor Production: Hurdles and Challenges Ahead
  • Big Tech Layoffs Lead to a Booming Demand for Skilled Workers

App Coding

Amazon MWS Integration from Celigo Now Available on SAP® Store
Zype Releases New Feature-Rich Apps Creator for OTT
Code Intelligence raises $12M Series A
Platform.sh Secures $140 million in Series D Funding to Support Enterprises in Scaling Fleets of Websites and Applications
Jotform Store Builder launches as a no-code solution to build a store in minutes

API Coding

RapidAPI opens European headquarters at the new location in Berlin
What is an API Gateway?
Creating an API that generates a description of an image using ChatGPT
The API Security Imperative
Apiiro Extends Right from Code to Runtime To Help Developers Fix Risks Faster

Blockchaining

What is a blockchain domain?
Join Our Team as a Blockchain Developer - Revolutionize the Future
Bit.Store Platform Launches Social-Fi Collaborative Investment
Wecan launches a blockchain along with its token and successfully completes its first private pre-sale
Corporate leaders should embrace the potential of blockchain technology before it gets used against them

Event Calendar

NAHB International Builders’ Show (IBS 2023) in Las Vegas from January 31 to February 2, 2023
India’s largest biennial automobile exhibition Auto Expo 2023 held on January 12-15, 2023 at Pragati Maidan, New Delhi
NRF 2023, Retail’s Big Show and Expo, January 15 to 17, 2023, Jacob K. Javits Center, New York
DOMOTEX Hannover 2023′ in Germany from 12-15 January
Electrify Expo Austin Set to Be Largest EV Demo Event of the 2022 Season, November 12-13, 2022, Austin, Texas

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT